Stay current in the rapid expansion of immunotherapies for the treatment of melanoma. Don’t miss out on expert discussions on current and emerging checkpoint inhibitors and intralesional therapies, combination therapy options, and the latest in other immune-based therapies for the treatment of melanoma.
XX AMA PRA Category 1 Credits™
Dec 21, 2018
Dec 21, 2019
Checkpoint Inhibitor Therapy in Melanoma
Jeffrey S. Weber, MD, PhD
Intralesional Therapies in Melanoma
Patrick Ott, MD, PhD
Combining Intralesional Therapies and Checkpoint Inhibitors
Sanjiv Agarwala, MD
Sanjiv Agarwala, MDSt Luke’s University Hospital and Temple University
Easton, Pennsylvania, United States
Patrick Ott, MD, PhDDana-Farber Cancer Institute
Boston, Massachusetts, United States
Jeffrey S. Weber, MD, PhDLaura and Isaac Perlmutter Cancer Center
NYU Langone Medical Center
New York, New York, United States
This educational activity is specifically designed to meet the needs of medical oncologists, dermatologists, surgeons, and other healthcare professionals involved in the treatment of melanoma.
After successful completion of this educational activity, participants should be able to:
- Assess recent efficacy and safety data on the use of immune-based therapies (eg, checkpoint inhibitors and intralesional therapies) in the management of melanoma
- Discuss the scientific rationale for combining immune-based therapies being used to treat melanoma
- Develop optimal treatment strategies using immune-based therapies for patients with melanoma
This educational activity is supported by a grant from Merck and Co, Inc.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this live activity for a maximum of XX AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Agarwala has disclosed that he has received consulting fees from Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Ott has disclosed that he has received consulting fees from CytomX and Novartis. He has also disclosed that he has performed contracted research for Amgen, Armo BioSciences, AstraZeneca/Medimmune, Bristol-Myers Squibb, Celldex, CytomX, Neon Therapeutics, Novartis, Pfizer, and Roche/Genentech, and has received funding for speaking and teaching from Oncoclinicas Brazil and the Chemofoundation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Weber has disclosed that he has received consulting fees from Altor, AstraZeneca, Biond, Bristol-Myers Squibb, Celldex, CytomX, Genentech, GlaxoSmithKline, Incyte, Merck, Sellas, and Takeda, and has been a member on an advisory committee or review panel for Bristol-Myers Squibb, Celldex, CytomX, GlaxoSmithKline, Merck, Pfizer, and Sellas. He has further disclosed intellectual property rights and/or ownership interest in Altor, Biodesix, Biond, and CytomX and is named in a CTLAX biomarker patent by Moffitt. He is also named in a PDI biomarker patent by Biodesix. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD(medical director content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.